Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets
Abstract Background Traditional nanodrug delivery systems have some limitations, such as eliciting immune responses and inaccuracy in targeting tumor microenvironments. Materials and methods Targeted drugs (Sorafenib, Sora) nanometers (hollow mesoporous silicon, HMSN) were designed, and then coated...
Main Authors: | Xuanbo Da, Bangping Cao, Jiantao Mo, Yukai Xiang, Hai Hu, Chen Qiu, Cheng Zhang, Beining Lv, Honglei Zhang, Chuanqi He, Yulong Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-02-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-024-12006-1 |
Similar Items
-
Tumor microenvironment responsive nano-platform for overcoming sorafenib resistance of hepatocellular carcinoma
by: Wenjing Xu, et al.
Published: (2024-02-01) -
Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization
by: Osman Öcal, et al.
Published: (2024-04-01) -
Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma
by: Shuhua Wei, et al.
Published: (2023-07-01) -
The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma
by: Siqi Chen, et al.
Published: (2023-07-01) -
Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01)